세계의 소양증 치료제 시장 - 규모, 점유율, 동향 분석 보고서 : 질환별, 제품별, 유통 채널별, 지역별 부문 예측(2025-2030년)

Pruritus Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Product, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 소양증 치료제 시장 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면, 세계의 소양증 치료제 시장 규모는 2030년까지 113억 4,000만 달러에 이르고, 2025-2030년까지 CAGR은 4.1%를 나타낼 것으로 예측됩니다.

아토피 피부염, 알레르기성 접촉 피부염, 두드러기 유병률 증가가 예측 기간 동안 시장 성장을 가속할 것으로 보입니다. 새로운 T세포 서브세트, 특히 Th17, Th22의 동정과 PROTOPIC(타크로리무스)의 특허 만료 등, 과학적인 메커니즘 해명에 의한 신제품의 도입은 예측 기간 중, 제조업체에게 새로운 활로를 열 것으로 기대됩니다.

코르티코스테로이드는 염증과 가려움증을 억제하여 가려움증 치료에 높은 효과를 발휘하기 때문에 2013년 주요 제품 부문이 되었습니다. 코르티코스테로이드의 국소 적용은 소양증의 치료 및 유지 요법에 매우 효과적인 것으로 밝혀졌습니다.

소양증 치료제 시장 보고서 하이라이트

• 코르티코스테로이드가 시장을 독점하고 2024년에는 28.1%의 점유율을 차지했습니다. 항히스타민 약물은 예측 기간 동안 상당한 성장이 예상됩니다.
• 병원 약국이 시장을 독점하고 2024년에는 49.8%의 점유율을 차지했습니다. 온라인 약국은 예측 기간 동안 CAGR 5.9%에서 가장 빠른 성장이 예측됩니다.
• 북미의 소양증 치료제 시장은 2024년 38.7%의 수익 점유율로 세계 시장을 독점했습니다. 미국의 소양증 치료제 시장은 2024년 90.1%의 수익 점유율로 북미의 소양증 치료제 시장을 독점했습니다.
• 아시아태평양의 소양증 치료제 시장은 예측 기간 동안 가장 빠른 CAGR 6.1%를 기록할 전망입니다. 아시아태평양 시장 중 인도의 소양증 치료제 시장은 예측 기간 동안 가장 빠른 속도로 성장할 것으로 예측됩니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 소양증 치료제 시장의 변수, 동향, 범위

• 시장 계통의 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 비즈니스 환경 분석
  • 산업 분석 - Porter's Five Forces 분석
  • PESTLE 분석

제4장 소양증 치료제 시장 : 질환 비즈니스 분석

• 질병 시장 점유율, 2024년과 2030년
• 질병 부문 대시보드
• 시장 규모와 예측과 동향 분석, 질환별, 2018-2030년
• 아토피 피부염
• 알레르기성 접촉 피부염
• 두드러기
• 기타

제5장 소양증 치료제 시장 : 제품 비즈니스 분석

• 제품 시장 점유율, 2024년과 2030년
• 제품 부문 대시보드
• 시장 규모와 예측과 동향 분석, 제품별, 2018-2030년
• 코르티코스테로이드
• 항히스타민제
• 국소 마취제
• 항자극제
• 면역 억제제
• 칼시뉴린 억제제
• 기타

제6장 소양증 치료제 시장 : 유통 채널 비즈니스 분석

• 유통 채널 시장 점유율, 2024년과 2030년
• 유통 채널 부문 대시보드
• 시장 규모와 예측과 동향 분석, 유통 채널별, 2018-2030년
• 병원 약국
• 소매 약국
• 온라인 약국

제7장 소양증 치료제 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석, 2024년과 2030년
• 지역별 시장 대시보드
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 국가별, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 국가별, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 덴마크
  • 스웨덴
• 아시아태평양
  • 국가별, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 국가별, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 국가별, 2018-2030년
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 참가자 개요
• 기업의 시장 포지셔닝 분석
• 기업 분류
• 전략 매핑
• 기업 프로파일/상장 기업
  • AbbVie Inc.
  • Amgen, Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb
  • Cara Therapeutics
  • GSK plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd

JHS

영문 목차

영문목차

Pruritus Therapeutics Market Growth & Trends:

The global Pruritus Therapeutics market size is expected to reach USD 11.34 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period.

Corticosteroids were the leading product segment in 2013 owing to high efficacy exhibited by this class of drugs in treating pruritic conditions by reducing inflammation and itching. Topical applications of corticosteroids have been found to be extremely effective in the treatment and maintenance therapies pertaining to pruritus.

Pruritus Therapeutics Market Report Highlights:

• Corticosteroids dominated the market and accounted for a share of 28.1% in 2024. Antihistamines are expected to register significant growth over the forecast period.
• Hospital pharmacies dominated the market and accounted for a share of 49.8% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 5.9% over the forecast period.
• North America pruritus therapeutics market dominated the global market with a revenue share of 38.7% in 2024. The pruritus therapeutics market in the U.S. dominated the North America pruritus therapeutics market with a revenue share of 90.1% in 2024.
• Asia Pacific pruritus therapeutics market is expected to register the fastest CAGR of 6.1% in the forecast period. India pruritus therapeutics market is expected to grow at the fastest rate over the forecast period in the Asia Pacific market.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease
  • 1.2.2. Product
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Pruritus Therapeutics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Pruritus Therapeutics Market: Disease Business Analysis

• 4.1. Disease Market Share, 2024 & 2030
• 4.2. Disease Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
• 4.4. Atopic Dermatitis
  • 4.4.1. Atopic Dermatitis Market, 2018 - 2030 (USD Million)
• 4.5. Allergic Contact Dermatitis
  • 4.5.1. Allergic Contact Dermatitis Market, 2018 - 2030 (USD Million)
• 4.6. Urticaria
  • 4.6.1. Urticaria Market, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Pruritus Therapeutics Market: Product Business Analysis

• 5.1. Product Market Share, 2024 & 2030
• 5.2. Product Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 5.4. Corticosteroids
  • 5.4.1. Corticosteroids Market, 2018 - 2030 (USD Million)
• 5.5. Antihistamines
  • 5.5.1. Antihistamines Market, 2018 - 2030 (USD Million)
• 5.6. Local Anesthetics
  • 5.6.1. Local Anesthetics Market, 2018 - 2030 (USD Million)
• 5.7. Counterirritants
  • 5.7.1. Counterirritants Market, 2018 - 2030 (USD Million)
• 5.8. Immunosuppressant
  • 5.8.1. Immunosuppressant Market, 2018 - 2030 (USD Million)
• 5.9. Calcineurin Inhibitors
  • 5.9.1. Calcineurin Inhibitors Market, 2018 - 2030 (USD Million)
• 5.10. Others
  • 5.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Pruritus Therapeutics Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2024 & 2030
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 7. Pruritus Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. North America Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Regulatory Framework
    • 7.4.2.3. Competitive Insights
    • 7.4.2.4. U.S. Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Regulatory Framework
    • 7.4.3.3. Competitive Insights
    • 7.4.3.4. Canada Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Regulatory Framework
    • 7.4.4.3. Competitive Insights
    • 7.4.4.4. Mexico Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Regulatory Framework
    • 7.5.2.3. Competitive Insights
    • 7.5.2.4. UK Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Regulatory Framework
    • 7.5.3.3. Competitive Insights
    • 7.5.3.4. Germany Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Regulatory Framework
    • 7.5.4.3. Competitive Insights
    • 7.5.4.4. France Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Regulatory Framework
    • 7.5.5.3. Competitive Insights
    • 7.5.5.4. Italy Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Regulatory Framework
    • 7.5.6.3. Competitive Insights
    • 7.5.6.4. Spain Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Norway
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Regulatory Framework
    • 7.5.7.3. Competitive Insights
    • 7.5.7.4. Norway Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Regulatory Framework
    • 7.5.8.3. Competitive Insights
    • 7.5.8.4. Denmark Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Sweden
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Regulatory Framework
    • 7.5.9.3. Competitive Insights
    • 7.5.9.4. Sweden Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Regulatory Framework
    • 7.6.2.3. Competitive Insights
    • 7.6.2.4. Japan Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Regulatory Framework
    • 7.6.3.3. Competitive Insights
    • 7.6.3.4. China Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Regulatory Framework
    • 7.6.4.3. Competitive Insights
    • 7.6.4.4. India Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Regulatory Framework
    • 7.6.5.3. Competitive Insights
    • 7.6.5.4. South Korea Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. Australia
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Regulatory Framework
    • 7.6.6.3. Competitive Insights
    • 7.6.6.4. Australia Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Regulatory Framework
    • 7.6.7.3. Competitive Insights
    • 7.6.7.4. Thailand Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Regulatory Framework
    • 7.7.2.3. Competitive Insights
    • 7.7.2.4. Brazil Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Regulatory Framework
    • 7.7.3.3. Competitive Insights
    • 7.7.3.4. Argentina Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Pruritus Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Regulatory Framework
    • 7.8.2.3. Competitive Insights
    • 7.8.2.4. South Africa Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Regulatory Framework
    • 7.8.3.3. Competitive Insights
    • 7.8.3.4. Saudi Arabia Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Regulatory Framework
    • 7.8.4.3. Competitive Insights
    • 7.8.4.4. UAE Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Regulatory Framework
    • 7.8.5.3. Competitive Insights
    • 7.8.5.4. Kuwait Pruritus Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. AbbVie Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. Amgen, Inc.
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Astellas Pharma Inc.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Bristol-Myers Squibb
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Cara Therapeutics
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. GSK plc
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Novartis AG
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Pfizer Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives
  • 8.5.9. Sanofi
    • 8.5.9.1. Overview
    • 8.5.9.2. Financial Performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic Initiatives
  • 8.5.10. Teva Pharmaceutical Industries Ltd
    • 8.5.10.1. Overview
    • 8.5.10.2. Financial Performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic Initiatives

관련자료